Advanced Digital Information
skyrocketed in after-hours trading Tuesday on news that the data storage company agreed to be acquired by
for about $770 million.
Advanced Digital shareholders will receive either $12.25 a share in cash or 3.461 shares of Quantum stock for each share they own. The $12.25 price represents a 48% premium over Tuesday's regular-session closing price of $8.27. Quantum anticipates that the deal will add up to 15 cents to its adjusted earnings in the first full year after closing, which is expected within three to four months. Shares of Advanced Digital jumped $3.63, or 44%, to $11.90 in late trading. Quantum slipped 8 cents, or 2.3%, to $3.40.
shares tumbled after the biopharmaceutical company's first-quarter results came in well below Wall Street's forecasts. The company's loss narrowed to $26.2 million, or 23 cents a share, from $83.9 million, or 87 cents a share, a year ago. Excluding items, earnings were $2.5 million, or 2 cents a share, compared with roughly break-even adjusted results last year. Revenue rose to $90.5 million from $38.8 million a year ago. Analysts polled by Thomson First Call expected earnings of 14 cents a share, on revenue of $103.3 million.
For the full year, PDL forecast earnings of 7 cents to 19 cents a share. The company anticipates 2006 revenue of $400 million to $430 million. Analysts project earnings of 44 cents a share and revenue of $429.1 million. Shares dropped $3.34, or 12%, to $24.25 in late trading.
sank after the company's adjusted earnings, as well as its revenue guidance, fell short of Wall Street's expectations. The company, which makes chips used in flat-panel displays, posted a fourth-quarter loss of $3170,000, or 1 cent a share, narrowed from a loss of $6.8 million, or 20 cents a share, a year earlier. Excluding amortization and stock-option charges, earnings were $1.6 million, or 4 cents a share, a penny below analysts' mean estimate. Revenue for the March quarter rose to $60.9 million from $52.9 million last year, topping Wall Street's projection of $60.5 million.
For the June quarter, Genesis forecast revenue of $55 million to $60 million. Analysts, on average, predict revenue of $65.3 million. Genesis shares fell $1.27, or 7.9%, to $14.84 in after-hours trading.
surged after the company topped Wall Street's fiscal second-quarter earnings expectations. The company, which makes hardware and software used to manufacture semiconductors, reported net earnings of $5.9 million, or 8 cents a share. Excluding charges and special items, earnings were 22 cents a share, well above analyst's average estimate of 14 cents a share. Revenue totaled $169.2 million, compared with Wall Street's target of $156.7 million. Brooks didn't provide year-ago information.
For the current quarter, the company sees earnings of 14 cents to 20 cents a share, including about 9 cents a share in special items, on revenue of $170 million to $180 million. Analysts, which usually exclude items from their forecasts, are looking for earnings of 21 cents a share, with revenue of $170.6 million.
Brooks also said it expects to delay the filing of its quarterly report. A special committee of independent directors is reviewing the granting of stock options to employees and directors of the company. Brooks said it doesn't expect to file its fiscal second-quarter 10-Q until the committee has completed its review, due in part to the potential impact of the review on prior years' results. Shares climbed $1.24, or 9%, to $14.70 after hours.
advanced after the maker of software for health care providers posted first-quarter earnings that beat projections. The company reported income of $1.32 million, or 3 cents a share, down slightly from $1.33 million, or 3 cents a share, a year ago. Excluding items, earnings jumped to 13 cents a share from 7 cents a year ago, exceeding Wall Street's prediction of 8 cents. Revenue climbed to $42.2 million from $26.2 million, well above analysts' forecast of $33.6 million. Shares rose $2.45, or 14%, to $19.60 in after-hours trading.
said the Food and Drug Administration recommended that the company conduct a new clinical trial for its PREOS osteoporosis drug, sending shares plummeting in after-hours trading. "We are carefully evaluating our options," Tony Coles, NPS president and chief operating officer, said in a statement, "but believe we could be in a position to file the amendment to our (new drug application) by the end of this year or early next year that addresses the issues raised in the March 9 approvable letter. We remain committed to getting PREOS approved."
NPS also reported that its first-quarter loss narrowed to $38.3 million, or 83 cents a share, from $45 million, or $1.16 a share, a year ago. Revenue rose to $6.1 million from $1.6 million last year. Analysts anticipated a loss of $1.03 a share and revenue of $4.9 million. Shares fell $1.66, or 20%, to $6.55 after hours Tuesday.